{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T23:46:57Z","timestamp":1784677617744,"version":"3.55.0"},"reference-count":13,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9S","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Dermatol Surg","DS"],"published-print":{"date-parts":[[2024,9]]},"abstract":"<jats:sec>\n            <jats:title>BACKGROUND<\/jats:title>\n            <jats:p>Botulinum neurotoxins produced by <jats:italic toggle=\"yes\">Clostridium botulinum<\/jats:italic> consist of a complex of a core neurotoxin protein and one or more nontoxin accessory proteins. The accessory proteins are generally thought to protect the neurotoxin from the gastric environment in botulism poisoning, dissociating away upon absorption. Other than their questionable immunogenicity, they are rarely mentioned in botulinum toxin therapy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>OBJECTIVE<\/jats:title>\n            <jats:p>To review evidence that accessory proteins potentially play a role in neurotoxin activity.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>RESULTS<\/jats:title>\n            <jats:p>Evidence suggests that the accessory proteins do not dissociate from the neurotoxin complex and enhance neurotoxin activity. Complexed type A botulinum toxin has dramatically higher endopeptidase activity than noncomplexed neurotoxin. A primary accessory protein, hemagglutinin-33, exhibits this same effect on both type A and type E core neurotoxin proteins, the latter not natively having this accessory protein. A clinical study using an objective computer assessment assay has shown a correlation between type A complex size and glabellar strain reduction, which reflects increasing clinical efficacy. Finally, a systematic review found no correlation between type A complex size and neutralizing antibody formation.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSION<\/jats:title>\n            <jats:p>Accessory proteins may play a role in the efficacy of botulinum toxin and could remain complexed to the neurotoxin for longer than previously reported.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/dss.0000000000004284","type":"journal-article","created":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T15:00:16Z","timestamp":1718204416000},"page":"S38-S41","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":7,"title":["Botulinum Toxin Accessory Proteins: Are They Just an Accessory?"],"prefix":"10.1097","volume":"50","author":[{"given":"Rui","family":"Avelar","sequence":"first","affiliation":[{"name":"Evolus, Inc., Newport Beach, California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,7,1]]},"reference":[{"key":"R1-20241006","first-page":"227","article-title":"Botulinum toxin type A products are not interchangeable: a review of the evidence","volume":"8","author":"Brin","year":"2014","journal-title":"Biologics"},{"key":"R2-20241006","doi-asserted-by":"crossref","first-page":"58","DOI":"10.3390\/toxins13010058","article-title":"Botulinum toxin: an update on pharmacology and newer products in development","volume":"13","author":"Choudhury","year":"2021","journal-title":"Toxins"},{"key":"R8-20241006","first-page":"21","article-title":"Assembly and function of the botulinum neurotoxin progenitor complex","volume":"364","author":"Gu","year":"2013","journal-title":"Curr Top Microbiol Immunol"},{"key":"R9-20241006","doi-asserted-by":"crossref","first-page":"6903","DOI":"10.1021\/bi990086c","article-title":"Enhancement of the endopeptidase activity of botulinum neurotoxin by its associated proteins and dithiothreitol","volume":"38","author":"Cai","year":"1999","journal-title":"Biochemistry"},{"key":"R10-20241006","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.toxicon.2010.12.019","article-title":"Studies on the dissociation of botulinum neurotoxin type A complexes","volume":"57","author":"Eisele","year":"2011","journal-title":"Toxicon"},{"issue":"Suppl 3","key":"R11-20241006","doi-asserted-by":"crossref","first-page":"S344","DOI":"10.1097\/DSS.0000000000001412","article-title":"The use of botulinum neurotoxin type A in aesthetics: key clinical postulates","volume":"43","author":"Nestor","year":"2017","journal-title":"Dermatol Surg"},{"key":"R12-20241006","doi-asserted-by":"crossref","first-page":"4791","DOI":"10.1021\/bi0355544","article-title":"Enhancement of the endopeptidase activity of purified botulinum neurotoxins A and E by an isolated component of the native neurotoxin associated proteins","volume":"43","author":"Sharma","year":"2004","journal-title":"Biochemistry"},{"key":"R13-20241006","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1097\/PRS.0000000000002076","article-title":"A quantitative analysis of onabotulinumtoxinA, abobotulinumtoxinA, and incobotulinumtoxinA: a randomized, double-blind, prospective clinical trial of comparative dynamic strain reduction","volume":"137","author":"Wilson","year":"2016","journal-title":"Plast Reconstr Surg"},{"key":"R14-20241006","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1111\/ced.12362","article-title":"Comparison of efficacy and diffusion of three formulations of botulinum toxin type A in two patients with forehead hyperhidrosis","volume":"39","author":"Ko","year":"2014","journal-title":"Clin Exp Dermatol"},{"key":"R15-20241006","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s00403-011-1179-z","article-title":"Comparison of the spread of three botulinum toxin type A preparations","volume":"304","author":"Kerscher","year":"2012","journal-title":"Arch Dermatol Res"},{"key":"R16-20241006","first-page":"s5","article-title":"Re-examining the optimal use of neuromodulators and the changing landscape: a consensus panel update","volume":"19","author":"Kaminer","year":"2020","journal-title":"J Drugs Dermatol"},{"key":"R17-20241006","first-page":"325","article-title":"Complexing proteins in botulinum toxin type A drugs: a help or a hindrance?","volume":"4","author":"Frevert","year":"2010","journal-title":"Biologics"},{"key":"R18-20241006","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1097\/PRS.0000000000008904","article-title":"Botulinum toxin type A immunogenicity across multiple indications: an overview systematic review","volume":"149","author":"Rahman","year":"2022","journal-title":"Plast Reconstr Surg"}],"container-title":["Dermatologic Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/DSS.0000000000004284","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,6]],"date-time":"2024-10-06T03:14:46Z","timestamp":1728184486000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/DSS.0000000000004284"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,1]]},"references-count":13,"journal-issue":{"issue":"9S","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/dss.0000000000004284","relation":{},"ISSN":["1076-0512","1524-4725"],"issn-type":[{"value":"1076-0512","type":"print"},{"value":"1524-4725","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,1]]}}}